Prospective , single center ,single blinded, randomized controlled  study on evaluation of use of , “AyurCoro3” as an adjuvant  for the treatment purpose in mild to moderate COVID-19 patients at tertiary care center.Study procedures shall be initiated post obtaining written informed consent process, as per local regulatory requirements. Randomization of the groups would be done as per computer generated charts , details of the randomization are as per below mentioned chart.  Randomization chart is enclosed along with the protocol for reference .

The participants were randomly allotted in the ratio 1:1 using a computer-generated random-number list to either the ’Control Arm’ (‘Standard of  Care’) or the ’Intervention Arm’ (Study  Medicine as an adjuvant to ’Standard of Care’). A total of 500 Patients would be randomized,250 in Control and 250 in Interventions. The participants wont not incur any personal cost owing to the study .

The randomization sequence with a size of 4 was generated by a statistician who was not part of the study team. Eligible patients are allocated to receive medication, according to the sequential order. Envelopes are prepared for emergency unmasking. Laboratory technicians are blinded to treatment allocation. The evaluators and statisticians are blinded until the completion of the visit and analysis. Data validation, cleaning and statistical analysis are done by trial researchers in collaboration with the Indian Institute of Technology Bombay (IIT Bombay), India. A Dedicated Research Coordinator who had no involvement in the participant enrollment,  would be doing the random allocation. ". After ensuring eligibility of patients, a Dedicated Research Coordinator would communicate the  assigned treatment to the recruiting investigator.

Study doctor will follow up telephonically 1 week post discharge to enquire study participants about their health status for functional status scale -post covid-19  .